[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-345690-105":59,"doc-detail-345690-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","patient-derived-organoids-across-cancers-reveal-conserved-tumor-heterogeneity-and-actionable-therapeutic-vulnerabilities","Patient-derived organoids across cancers reveal conserved tumor heterogeneity and actionable therapeutic vulnerabilities","","Patient-derived organoid (PDO) platform is established across 15 cancer types, generating 220 PDOs from 191 patients to support functional precision oncology. Comprehensive characterization confirms high fidelity to parent tumors: 93% histopathology concordance, 80% median genomic concordance for driver mutations, and a 0.85 median gene expression correlation, with stability across 10 passages. Clonality analysis shows 85% preservation of dominant clones, and functional assays identify talazoparib sensitivity in models lacking eligibility for FDA-approved PARP inhibitors. Combination screens also reveal approaches to overcome TP53-mutant resistance.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/patient-derived-organoids-across-cancers-reveal-conserved-tumor-heterogeneity-and-actionable-therapeutic-vulnerabilities/345690/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/patient-derived-organoids-across-cancers-reveal-conserved-tumor-heterogeneity-and-actionable-therapeutic-vulnerabilities/345690.png","ImageObject",300,407,{"name":92,"@type":93},"River Wang","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-14","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"How many organoids and patients are included in the pan-cancer PDO platform?","Question",{"text":113,"@type":114},"The platform comprises 220 patient-derived organoids from 191 patients across 15 cancer types.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What measures show that PDOs retain fidelity to the original tumors?",{"text":118,"@type":114},"The study reports 93% histopathology concordance, 80% median genomic concordance for driver mutations, and a 0.85 median gene expression correlation, with stability over 10 passages.",{"name":120,"@type":111,"acceptedAnswer":121},"Which therapeutic vulnerability did the functional assays identify?",{"text":122,"@type":114},"Functional assays found that 58% of PDOs from patients not eligible for FDA-approved PARP inhibitors were sensitive to talazoparib, linked to DNA damage repair alterations.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},345690,1790386019,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},1099514067438,"https://ap-avatar.wpscdn.com/avatar/100002539ee87300030?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780474512215547542","CANCER  \nPatient-derived organoids across cancers reveal conserved tumor heterogeneity and actionable therapeutic vulnerabilities  \nHui-Hsuan Kuo1†, Bhavneet Bhinder1,2†, Hamza N. Gokozan3, Kathryn Gorski1,3, Pooja Chandra1,3, Jyothi Manohar1, Daniela Guevara1, John Otilano1, Jenna Moyer1, Marvel Tranquille1,  \nSarah Ackermann1, Jared Capuano1, Cynthia Cheung1, Thomas A. Caiazza1, Phoebe L. Reuben1, Anastasia Murray Tsomides1, Adriana Irizarry1, Michael Sigouros1, David Wilkes1, Abigail King1, Troy Kane1, Majd Al Assaad1,3, Wael Al Zoughbi1,3, Kentaro Ohara1,3, Joonghoon Auh1,  \nPeter Waltman1,2, Florencia P. Madorsky Rowdo1, Enrique Podaza1, Valerie Gallegos1,  \nJohn Nguyen1, Raehash Shah1, Manish Shah1, Allyson Ocean1, Douglas Scherr4, Nasser Altorki5, Melissa Frey6, Ana M. Molina7, Lisa Newman1, Vivan Bea8,9, Eloise Chapman-Davis1,  \nMarcus D. Goncalves7, Ashish Saxena1, Parul J. Shukla8, Kevin Holcomb6, Rachel Simmons1, Scott Tagawa1, Jonathan H. Zippin1,10, Evelyn Cantillo1, Rohit Chandwani8,11, Melissa Davis1, Kelly Garrett8, Pashtoon M. Kasi1, Jennifer Marti1, David Nanus12, Jones T. Nauseef, Elizabeth Popa1, MominT. Siddiqui3, Alicia Alonso1, Cora N. Sternberg1, Bishoy M. Faltas1, Olivier Elemento1,2,13, Juan Miguel Mosquera1,3‡, Andrea Sboner1,2,14‡, M. Laura Martin1*‡  \nWe developed a pan-cancer patient-derived organoid (PDO) platform comprising 220 PDOs from 191 patients across 15 cancer types to advance functional precision oncology. Comprehensive characterization demonstrated high fidelity to parent tumors, with 93% histopathology concordance, 80% median genomic concordance for driver mutations, and a 0.85 median gene expression correlation. Expression profiles remained largely stable over 10 passages, ensuring reproducibility for long-term screening. Clonality analysis showed that 85% of dominant tumor clones were preserved, with genomic concordance directly reflecting clonal similarity. Even PDOs with lower concordance retained key oncogenic drivers, validating their utility as disease models. Functional assays revealed that 58% of PDOs from patients ineligible for US Food and Drug Administration–approved poly(adenosine 5 ′-diphosphate– ribose) polymerase inhibitors were sensitive to talazoparib, linked to DNA damage repair alterations. Furthermore, combination screens identified agents that overcome resistance, particularly in TP53-mutant models. Our platform enables the investigation of targeted therapies and molecular drivers of drug sensitivity, providing translational insights for personalized treatment beyond current biomarker guidelines.  \ncopyright © 2026 the Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. no claim to original U.S.  \nGovernment Works. distributed under a creative commons Attribution noncommercial license 4.0 (cc BY-nc) .  \nINTRODUCTION  \nFunctional precision oncology platforms enable direct testing of cancer therapies in patient-derived tumor tissues, identifying vulnerabilities that may not be detectable through molecular profiling alone (1, 2). This approach, crucial for advancing precision medicine, addresses  \n1englander institute for Precision Medicine, Weill cornell Medicine, new York, nY 10021, USA. 2institute for computational Biomedicine, Weill cornell Medicine, new York, nY 10021, USA. 3department of Pathology and laboratory Medicine, Weill cornell Medicine, new York, nY USA 10065. 4department of Urology, Weill cornell Medicine, new York, nY 10065 USA. 5 department of cardiothoracic Surgery, Weill cornell Medicine, new York, nY 10065 USA. 6department of Obstetricsand Gynecology, Weill cornell Medicine, new York, nY 10065, USA. 7department of Medicine, Weill cornell Medicine, new York, nY 10065 USA. 8department of Surgery, Weill cornell Medicine, new York, nY 10065 USA. 9newYork–Presbyterian Weill cornell Brooklyn Methodist hospital, Brooklyn, nY 11215 USA. 10department of dermatology, Weill cornell Medicine, new York, nY 10","cbCaijUPxgAwBxv9","https://ap.wps.com/l/cbCaijUPxgAwBxv9","pdf",5985268,22,"English","# Introduction\n## Functional precision oncology and PDO role\n## Need for standardization and validation\n## Challenges in existing PDO pipelines","[{\"question\":\"How many organoids and patients are included in the pan-cancer PDO platform?\",\"answer\":\"The platform comprises 220 patient-derived organoids from 191 patients across 15 cancer types.\"},{\"question\":\"What measures show that PDOs retain fidelity to the original tumors?\",\"answer\":\"The study reports 93% histopathology concordance, 80% median genomic concordance for driver mutations, and a 0.85 median gene expression correlation, with stability over 10 passages.\"},{\"question\":\"Which therapeutic vulnerability did the functional assays identify?\",\"answer\":\"Functional assays found that 58% of PDOs from patients not eligible for FDA-approved PARP inhibitors were sensitive to talazoparib, linked to DNA damage repair alterations.\"}]","Patient-derived organoids across cancers reveal conserved tumor heterogeneity and actionable therapeutic vulnerabilities | PDF",1790058627,55,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a3925daa808c75f617ceaf50263bf343.webp",983,1250,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/824a21cbf65ddc8eac9ef524367aa8c1.webp",982,1249,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/92f5e2ad1963f2f7948d7f8c4302f9b3.webp",981,1248,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fbf04e95b49984dd2d6466ee0931b572.webp",980,1247]